Kura Oncology KURA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$73.33M-27.7% | -$81M-321% | -$74.12M-36.2% | -$66.12M-30.1% | -$57.43M-16.0% | ||
| $355K+47.3% | $403K+97.5% | $164K-21.2% | $224K+10.9% | $241K+3.0% | ||
| $8.42M+7.3% | $11.35M+31.5% | $10.97M+31.7% | $6.95M-17.6% | $7.84M-7.9% | ||
| $106K-20.3% | $103K-26.4% | $141K+5.2% | $138K+8.7% | $133K+9.0% | ||
| $544K-98.8% | —— | —— | —— | $46.69M+8,965% | ||
| $430K+316% | $103.25K— | $103.25K— | $103.25K— | $103.25K— | ||
| $2.03M-35.5% | —— | $12.72M+124% | —— | $3.14M+200% | ||
| -$16.22M-88.3% | —— | —— | —— | -$8.61M-305% | ||
| $562K-45.9% | —— | $10.29M+2,982% | $7.51M+405% | $1.04M-52.5% | ||
| $204K-21.2% | $118K-49.8% | $297K+41.4% | $369K+156% | $259K+53.3% | ||
| -$9.44M-127% | $156.29M+125% | $15.66M-77.5% | $0-100% | $34.59M-50.3% | ||
| $3.78M+8,113% | —— | —— | —— | $46K— | ||
| -$85.85M-19.4% | —— | -$80.63M-85.6% | -$28.78M+32.3% | -$71.93M-47.3% | ||
| $128K-56.2% | $2.32M+524% | $2.57M— | $1.46M+9,013% | $292K+248% | ||
| $171.6M-36.1% | $239.78M-0.3% | $138.5M+124% | $114.6M-29.1% | $268.71M+37.8% | ||
| $147.5M-12.0% | $177.5M+21.6% | $235.03M+119% | $175M-14.6% | $167.6M+67.9% | ||
| -$24.23M+76.1% | -$64.6M+32.0% | $93.97M— | —— | -$101.41M-6.4% | ||
| $69K-51.7% | $1.14M+40.6% | $0-100% | $515K-83.1% | $143K-94.4% | ||
| —— | —— | —— | —— | —— | ||
| $69K-51.7% | $1.14M+40.8% | $0-100% | $515K-83.1% | $143K-99.9% | ||
| -$110.02M+36.5% | —— | —— | —— | -$173.19M-4,235% | ||
| $900K-66.2% | $1.38M-52.1% | $1.92M-44.0% | $2.52M-29.0% | $2.66M-18.6% | ||
| $106K-20.3% | $103K-26.4% | $141K+5.2% | $138K+8.7% | $133K+9.0% | ||
| $355K+47.3% | $403K+97.5% | $164K-21.2% | $224K+10.9% | $241K+3.0% | ||
| -$16.22M-88.3% | —— | —— | —— | -$8.61M-305% | ||
| $3.78M+8,113% | —— | —— | —— | $46K— | ||
| -$689K-139% | $558K+181% | $2.88M— | $1.17M+317% | $1.75M+859% | ||
| $204K-21.2% | $118K-49.8% | $297K+41.4% | $369K+156% | $259K+53.3% | ||
| $562K-45.9% | —— | $10.29M+2,982% | $7.51M+405% | $1.04M-52.5% | ||
| $171.6M-36.1% | $239.78M-0.3% | $138.5M+124% | $114.6M-29.1% | $268.71M+37.8% | ||
| $147.5M-12.0% | $177.5M+21.6% | $235.03M+119% | $175M-14.6% | $167.6M+67.9% | ||
| $69K-51.7% | $1.14M+40.6% | $0-100% | $515K-83.1% | $143K-94.4% | ||
| -$9.44M-127% | $156.29M+125% | $15.66M-77.5% | $0-100% | $34.59M-50.3% | ||
| $3.78M+8,113% | —— | —— | —— | $46K— | ||
| -$85.98M-19.1% | —— | -$83.19M-91.5% | -$30.24M+28.9% | -$72.22M-47.6% | ||
| -$85.98M-19.1% | —— | -$83.19M-91.5% | -$30.24M+28.9% | -$72.22M-47.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kura Oncology generate?
- Kura Oncology (KURA) generated -$267.2M in operating cash flow over the trailing twelve months.
- What is Kura Oncology's free cash flow?
- After $6.5M of capital expenditures, Kura Oncology's free cash flow was -$271.6M over the trailing twelve months, down 302.9% year over year.
- Where does Kura Oncology's cash flow data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
